Daily Intelligence Brief
Depo-Provera Docket Dominates Federal Mass Tort Landscape With 1,500+ Filings This Month
The Depo-Provera Products Liability Litigation (N.D. Fla., Judge M. Casey Rodgers) has absorbed more than 1,500 new complaints this month, dwarfing every other active pharmaceutical MDL and cementing meningioma claims as the fastest-growing mass tort of 2026. Recent filings include Monique Walker v. Pfizer Inc. (3:26-cv-03052) and Alberta Adams v. Pfizer Inc. (3:26-cv-03044) among hundreds of coordinated complaints alleging Pfizer's contraceptive injection causes brain tumors. Meanwhile, the Johnson & Johnson Talc Litigation in the District of New Jersey added 114 filings as post-verdict momentum from the $1.56 billion Baltimore award continues to drive enrollment. In a notable counterpoint, the first Paragard bellwether trial in the Paragard IUD Products Liability Litigation (N.D. Ga., Judge Leigh Martin May) concluded in February 2026 with a defense verdict for Teva Pharmaceuticals — the jury in Rickard v. Teva rejected claims that the IUD's design was defective, though nearly 4,000 cases remain pending and future trials are scheduled.Nevro Spinal Stimulator Complaints Surface In Coordinated California Filing Wave
Eight new spinal cord stimulator failure complaints targeting Nevro Corporation landed in California federal court in a concentrated March 23 filing surge, including Hawken v. Nevro Corporation (3:26-cv-02522) and Manley v. Nevro Corporation (4:26-cv-02507). The filings allege Nevro's HF10 therapy devices cause debilitating neurological complications, with plaintiffs claiming the company concealed adverse event data from physicians. Nevro is not currently named in the pending motion to consolidate the Abbott Labs and Boston Scientific Spinal Cord Stimulator Products Liability Litigation, which targets other device manufacturers — raising the question of whether plaintiff steering committees will seek to add Nevro as a primary defendant if consolidation is granted. The coordinated block signals renewed plaintiff bar interest in a litigation track that had seen limited federal activity in recent months.EtO Sterilization Litigation Sees Regulatory Pressure As EPA Maintains Enforcement Focus
The ethylene oxide sterilization litigation gained fresh regulatory momentum March 25 when EPA Region 6 released additional FOIA-responsive materials, continuing the agency's documentation of emissions violations at commercial sterilization facilities. The regulatory activity supports pending personal injury and property damage claims alleging cancer clusters near sterilization plants, with plaintiffs relying on EPA air monitoring data to establish exposure levels. No federal MDL has formed for EtO claims, which remain scattered across state and federal courts, but the sustained EPA enforcement posture provides plaintiffs with ongoing evidence development and potential parallel government enforcement theories.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
